Altimmune Inc - Bathi resik saben saham (EPS TTM) ALT

Altimmune, Inc. (ALT) develops advanced peptide therapies to combat obesity and liver pathologies. Pemvidutide holds particular potential by minimizing muscle loss, which enhances the company's capitalization. This price chart reflects the EPS (TTM) dynamics, which currently stand at 32.20. However, the success of the entire biotech sector depends on regulatory approval, as commercial sales have not yet been launched.

Altimmune Corp (ALT) - Bathi saben saham sajrone rolas wulan pungkasan saka 11.02.2024 nganti 15.11.2026

altimmune.com - rincian analitis lan metrik utama (ALT)

- rega saham lan target rega konsensus:

Rega Altimmune|ALT - Prakiraan konsensus analis

- rincian nilai pasar emiten:

Kapitalisasi pasar Altimmune Corp|ALT - Nilai Perusahaan

- data nilai buku modal saham:

Aset Bersih saben Siji Saham Altimmune|ALT - Nilai Buku Perusahaan|Koefisien Nilai Pasar marang Nilai Buku altimmune.com|ALT - Aset Agregat Perusahaan

- indikator total utang lan likuiditas perusahaan:

- indikator bathi lan kelipatan valuasi:

ALT - Bathi resik perusahaan|Bathi sing dikarepake Altimmune, Inc.|ALT - Koefisien rega marang bathi|Rasio kapitalisasi marang bathi mangsa ngarep Altimmune Corp|ALT - Pangali PEG|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan Altimmune Pharma|ALT - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Altimmune|ALT - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan altimmune.com|ALT - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Altimmune, Inc.

- rincian pendapatan lan dodolan:

ALT - Pendapatan perusahaan|Prakiraan pendapatan perusahaan Altimmune|ALT - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Altimmune

Analisis wiwitan perusahaan:ALT (Altimmune Inc)

Conservative capital demands absolute profit transparency to confirm the sustainability of the business model. This indicator measures the annual change in net income per share over the last 12 months, revealing the actual efficiency of cost and revenue management. For Altimmune, Inc. (ALT), this is a critical marker of the transition from the costly development of Pemvidutide to monetization within the obesity segment. By analyzing the EPS YoY TTM trend, investors assess the company's readiness to scale within the metabolic therapy market.

Analisis pesaing